BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 27211548)

  • 1. Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors.
    Holmgaard RB; Zamarin D; Lesokhin A; Merghoub T; Wolchok JD
    EBioMedicine; 2016 Apr; 6():50-58. PubMed ID: 27211548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.
    Holmgaard RB; Zamarin D; Munn DH; Wolchok JD; Allison JP
    J Exp Med; 2013 Jul; 210(7):1389-402. PubMed ID: 23752227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases.
    Thorn M; Guha P; Cunetta M; Espat NJ; Miller G; Junghans RP; Katz SC
    Cancer Gene Ther; 2016 Jun; 23(6):188-98. PubMed ID: 27199222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment.
    Schafer CC; Wang Y; Hough KP; Sawant A; Grant SC; Thannickal VJ; Zmijewski J; Ponnazhagan S; Deshane JS
    Oncotarget; 2016 Nov; 7(46):75407-75424. PubMed ID: 27705910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing of CSF-1/CSF-1R signaling blockade is critical to improving responses to CTLA-4 based immunotherapy.
    Holmgaard RB; Brachfeld A; Gasmi B; Jones DR; Mattar M; Doman T; Murphy M; Schaer D; Wolchok JD; Merghoub T
    Oncoimmunology; 2016 Jul; 5(7):e1151595. PubMed ID: 27622016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.
    Mok S; Tsoi J; Koya RC; Hu-Lieskovan S; West BL; Bollag G; Graeber TG; Ribas A
    BMC Cancer; 2015 May; 15():356. PubMed ID: 25939769
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer.
    Li F; Zhao Y; Wei L; Li S; Liu J
    Cancer Biol Ther; 2018 Aug; 19(8):695-705. PubMed ID: 29621426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of ROS in myeloid-derived suppressor cells through targeting fatty acid transport protein 2 enhanced anti-PD-L1 tumor immunotherapy.
    Adeshakin AO; Liu W; Adeshakin FO; Afolabi LO; Zhang M; Zhang G; Wang L; Li Z; Lin L; Cao Q; Yan D; Wan X
    Cell Immunol; 2021 Apr; 362():104286. PubMed ID: 33524739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoconjugates to enhance PDT-mediated cancer immunotherapy by targeting the indoleamine-2,3-dioxygenase pathway.
    Yang X; Zhang W; Jiang W; Kumar A; Zhou S; Cao Z; Zhan S; Yang W; Liu R; Teng Y; Xie J
    J Nanobiotechnology; 2021 Jun; 19(1):182. PubMed ID: 34127005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells.
    Li A; Barsoumian HB; Schoenhals JE; Cushman TR; Caetano MS; Wang X; Valdecanas DR; Niknam S; Younes AI; Li G; Woodward WA; Cortez MA; Welsh JW
    Cancer Lett; 2018 Sep; 431():54-63. PubMed ID: 29746927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma.
    Mao Y; Eissler N; Blanc KL; Johnsen JI; Kogner P; Kiessling R
    Clin Cancer Res; 2016 Aug; 22(15):3849-59. PubMed ID: 26957560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An albumin-bound drug conjugate of paclitaxel and indoleamine-2,3-dioxygenase inhibitor for enhanced cancer chemo-immunotherapy.
    Hu Z; Zheng B; Xu J; Gao S; Lu W
    Nanotechnology; 2020 May; 31(29):295101. PubMed ID: 32203949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (-)-4-O-(4-O-β-D-glucopyranosylcaffeoyl) Quinic Acid Inhibits the Function of Myeloid-Derived Suppressor Cells to Enhance the Efficacy of Anti-PD1 against Colon Cancer.
    Lin H; Wu Y; Chen J; Huang S; Wang Y
    Pharm Res; 2018 Jul; 35(9):183. PubMed ID: 30062658
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
    Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
    Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prim-O-glucosylcimifugin enhances the antitumour effect of PD-1 inhibition by targeting myeloid-derived suppressor cells.
    Gao W; Zhang X; Yang W; Dou D; Zhang H; Tang Y; Zhong W; Meng J; Bai Y; Liu Y; Yang L; Chen S; Liu H; Yang C; Sun T
    J Immunother Cancer; 2019 Aug; 7(1):231. PubMed ID: 31462297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid-derived suppressor cells suppress antitumor immune responses through IDO expression and correlate with lymph node metastasis in patients with breast cancer.
    Yu J; Du W; Yan F; Wang Y; Li H; Cao S; Yu W; Shen C; Liu J; Ren X
    J Immunol; 2013 Apr; 190(7):3783-97. PubMed ID: 23440412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer.
    Shi J; Liu C; Luo S; Cao T; Lin B; Zhou M; Zhang X; Wang S; Zheng T; Li X
    Cell Immunol; 2021 Aug; 366():104384. PubMed ID: 34182334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
    Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
    J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ganoderma lucidum polysaccharide (GLP) enhances antitumor immune response by regulating differentiation and inhibition of MDSCs via a CARD9-NF-κB-IDO pathway.
    Wang Y; Fan X; Wu X
    Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32530032
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinically feasible approaches to potentiating cancer cell-based immunotherapies.
    Seledtsov VI; Goncharov AG; Seledtsova GV
    Hum Vaccin Immunother; 2015; 11(4):851-69. PubMed ID: 25933181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.